Martin den Adel

Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor

Dorien Groenendaal‐van de Meent, Martin den Adel, Jan Noukens et al. · Clinical Drug Investigation · 2016 · 38 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Safety, and Tolerability of Roxadustat in Healthy Subjects

Dorien Groenendaal‐van de Meent, Martin den Adel, Jan van Dijk et al. · European Journal of Drug Metabolism and Pharmacokinetics · 2018 · 23 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +12

Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies

Tomohiro Kusawake, James J. Keirns, Donna Kowalski et al. · Advances in Therapy · 2017 · 21 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

The Hypoxia-inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat (FG-4592) and Warfarin in Healthy Volunteers: A Pharmacokinetic and Pharmacodynamic Drug–Drug Interaction Study

Dorien Groenendaal‐van de Meent, Martin den Adel, Sanne Rijnders et al. · Clinical Therapeutics · 2016 · 20 citations

Medicine, Pharmacokinetics, Pharmacology +14

Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor

Dorien Groenendaal‐van de Meent, Virginie Kerbusch, Rüdiger Kaspera et al. · European Journal of Drug Metabolism and Pharmacokinetics · 2020 · 17 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17